Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.56 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11592475 | 0.80 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL30998353 | 0.80 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL11592473 | 0.80 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL11592479 | 0.80 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL6924410 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HTR2A | |
| SCHEMBL18761532 | 0.76 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL29551852 | 0.76 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL18761548 | 0.76 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL22297031 | 0.76 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4IDO1HTR2A | |
| SCHEMBL18761528 | 0.76 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4IDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915268-B2 | And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, KIT, ADORA2A | SLC6A2 1155/4885SLC6A3 2070/4885SLC6A4 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.